ACHV
Price
$2.55
Change
-$0.00 (-0.00%)
Updated
Aug 15 closing price
Capitalization
130.32M
82 days until earnings call
ARCT
Price
$19.48
Change
+$0.25 (+1.30%)
Updated
Aug 15 closing price
Capitalization
528.97M
81 days until earnings call
Interact to see
Advertisement

ACHV vs ARCT

Header iconACHV vs ARCT Comparison
Open Charts ACHV vs ARCTBanner chart's image
Achieve Life Sciences
Price$2.55
Change-$0.00 (-0.00%)
Volume$639.78K
Capitalization130.32M
Arcturus Therapeutics Holdings
Price$19.48
Change+$0.25 (+1.30%)
Volume$994.18K
Capitalization528.97M
ACHV vs ARCT Comparison Chart in %
Loading...
ACHV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACHV vs. ARCT commentary
Aug 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACHV is a Hold and ARCT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 16, 2025
Stock price -- (ACHV: $2.55 vs. ARCT: $19.48)
Brand notoriety: ACHV and ARCT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACHV: 51% vs. ARCT: 173%
Market capitalization -- ACHV: $130.32M vs. ARCT: $528.97M
ACHV [@Biotechnology] is valued at $130.32M. ARCT’s [@Biotechnology] market capitalization is $528.97M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.71B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACHV’s FA Score shows that 0 FA rating(s) are green whileARCT’s FA Score has 0 green FA rating(s).

  • ACHV’s FA Score: 0 green, 5 red.
  • ARCT’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than ACHV.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACHV’s TA Score shows that 5 TA indicator(s) are bullish while ARCT’s TA Score has 6 bullish TA indicator(s).

  • ACHV’s TA Score: 5 bullish, 1 bearish.
  • ARCT’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ACHV is a better buy in the short-term than ARCT.

Price Growth

ACHV (@Biotechnology) experienced а +2.00% price change this week, while ARCT (@Biotechnology) price change was +63.56% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +9.90%. For the same industry, the average monthly price growth was +26.70%, and the average quarterly price growth was +20.91%.

Reported Earning Dates

ACHV is expected to report earnings on Nov 06, 2025.

ARCT is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+9.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($529M) has a higher market cap than ACHV($130M). ARCT YTD gains are higher at: 14.791 vs. ACHV (-27.557). ACHV has higher annual earnings (EBITDA): -44.37M vs. ARCT (-63.92M). ARCT has more cash in the bank: 217M vs. ACHV (23.2M). ACHV has less debt than ARCT: ACHV (9.96M) vs ARCT (42.7M). ARCT has higher revenues than ACHV: ARCT (131M) vs ACHV (0).
ACHVARCTACHV / ARCT
Capitalization130M529M25%
EBITDA-44.37M-63.92M69%
Gain YTD-27.55714.791-186%
P/E RatioN/AN/A-
Revenue0131M-
Total Cash23.2M217M11%
Total Debt9.96M42.7M23%
FUNDAMENTALS RATINGS
ACHV vs ARCT: Fundamental Ratings
ACHV
ARCT
OUTLOOK RATING
1..100
583
VALUATION
overvalued / fair valued / undervalued
1..100
51
Fair valued
46
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9995
PRICE GROWTH RATING
1..100
8438
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5047

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (46) in the Pharmaceuticals Major industry is in the same range as ACHV (51) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACHV’s over the last 12 months.

ARCT's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as ACHV (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACHV’s over the last 12 months.

ARCT's SMR Rating (95) in the Pharmaceuticals Major industry is in the same range as ACHV (99) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACHV’s over the last 12 months.

ARCT's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for ACHV (84) in the Biotechnology industry. This means that ARCT’s stock grew somewhat faster than ACHV’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ACHV (100) in the Biotechnology industry. This means that ARCT’s stock grew similarly to ACHV’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACHVARCT
RSI
ODDS (%)
N/A
Bearish Trend 1 day ago
85%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
68%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 5 days ago
85%
Bearish Trend 6 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
N/A
Bullish Trend 1 day ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ACHV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYPIX62.84N/A
N/A
Rydex Transportation Inv
FDEIX28.22N/A
N/A
Fidelity Advisor Capital Development I
HEMZX7.77N/A
N/A
Virtus SGA Emerging Markets Equity A
BNIEX12.07N/A
N/A
UBS International Sustainable Equity A
SXPCX52.55N/A
N/A
DWS S&P 500 Index C

ACHV and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACHV has been loosely correlated with ALT. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ACHV jumps, then ALT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACHV
1D Price
Change %
ACHV100%
N/A
ALT - ACHV
56%
Loosely correlated
-1.36%
ATNM - ACHV
38%
Loosely correlated
+2.42%
ABOS - ACHV
38%
Loosely correlated
+1.43%
ARCT - ACHV
36%
Loosely correlated
+1.30%
NAUT - ACHV
36%
Loosely correlated
-1.27%
More

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with CLDX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then CLDX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+1.30%
CLDX - ARCT
51%
Loosely correlated
+2.25%
RGNX - ARCT
51%
Loosely correlated
-2.65%
RXRX - ARCT
51%
Loosely correlated
+2.30%
BEAM - ARCT
51%
Loosely correlated
+1.08%
PDSB - ARCT
49%
Loosely correlated
-0.83%
More